Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society

RECOMMENDED

Further Publications

Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP, Rivera MP

doi: 10.1016/j.chest.2021.02.032

RECOMMENDED

Pleural Diseases

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Front Med (Lausanne)

Hindocha S, Campbell D, Ahmed M, Giorgakoudi K, Sharma B, Yousaf N, Molyneaux P, Hunter B, Kalsi H, Cui W, Davidson M, Bhosle J, Minchom A, Locke I, McDonald F, O'Brien M, Popat S, Lee RW

doi: 10.3389/fmed.2021.764563

Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines

Horak F, Doberer D, Eber E, Horak E, Pohl W, Riedler J, Szépfalusi Z, Wantke F, Zacharasiewicz A, Studnicka M

RECOMMENDED

Lung CancerPleural DiseasesFurther Publications

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

Chest.

Suresh K, Naidoo J, Lin CT, Danoff S

doi: 10.1016/

RECOMMENDED

Further Publications

Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med.

Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, San José Estépar R, Seo JB, Johkoh T, Sverzellati N, Ryerson CJ, Graham Barr R, Goo JM, Austin JHM, Powell CA, Lee KS, Inoue Y, Lynch DA

doi: 10.1016/S2213-2600(20)30168-5.

RECOMMENDED

Lung Cancer

Management of pulmonary toxicity associated with immune checkpoint inhibitors

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir Rev.

Delaunay M, Prévot G, Collot S, Guilleminault L, Didier A, Mazières J

doi: 10.1183/16000617.0012-2019.

RECOMMENDED

Lung Cancer

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Clin Lung Cancer.

Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Marco R, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K

doi: 10.1016/j.cllc.2020.06.010.

RECOMMENDED

Lung Cancer

Standardized reporting and management of suspicious findings on chest computed tomography is associated with improved lung cancer diagnosis in an observational study

★ 2 Recommended by Dr Martin Frey, Faculty Member

Chest.

Urbania TH, Dusendang JR, Herrinton LJ, Alexeeff S, Corley DA, Ely S, Patel A, Osinski T, Sakoda LC

doi: 10.1016/j.chest.2020.05.595.

Lung Cancer

Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC

Lung Cancer.

Crane G, Smoljanovic V, Khan N, Gally S, Tomasini P, Lara N, Gondos A, Hammerschmidt S

doi: 10.1016/j.lungcan.

Related content

Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications

Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society

Management of pulmonary toxicity associated with immune checkpoint inhibitors

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Standardized reporting and management of suspicious findings on chest computed tomography is associated with improved lung cancer diagnosis in an observational study

Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC